# Meitheal Pharmaceuticals expands heparin manufacturing capacity in China

Meitheal Pharmaceuticals announced FDA approval of a new vial manufacturing line at NKF's Nanjing facility, doubling vial capacity to 100 million units. Plans include additional lines and a second Nanjing facility under construction, plus a new vial line in Chengdu.

- Type: Expansion
- Announced: 2020-02-11
- Where: Nanjing, China; Chengdu, China, China
- Status: announced
- Capacity: 50 million units new vial capacity; combined 100 million units vial; 100 million units new pre-filled syringe line; combined 200 million units pre-filled syringe
- Products: heparin sodium injection
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Meitheal Pharmaceuticals](https://endata.com/companies/45182.md)
- [Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.](https://endata.com/companies/45183.md) (partner)

## Sources

- [pharmaceuticaldaily.com](https://pharmaceuticaldaily.com/meitheal-pharmaceuticals-announces-fda-approval-of-additional-manufacturing-capacity-and-future-facility-expansion-plans-for-production-of-heparin-sodium-injection-usp/), 2020-02-11: "The new line and future expansion plans (10 total manufacturing lines) supports Meitheal's majority shareholder, NKF's commitment to ensuring capacity to supply the US market for years to come."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.